Advanced Search


Study ID Status Title Patient Level Data
116482 Active, not recruiting A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of human immunodeficiency virus -1 (HIV-1) virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naive adult subjects
116483 Recruiting Protocol to evaluate the public health value of maraviroc using the French hospital databaseon HIV infection (FHDH)
116485 Completed Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants
116488 Active, Not Recruiting Drug Use Investigation for PAXIL Controlled-Release (CR)
116490 Completed REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA™
116492 Completed A 6-month, open label, randomised, efficacy study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via the Dry Powder Inhaler ELLIPTA™ compared with usual ICS/LABA maintenance therapy delivered by Dry Powder Inhaler in subjects with Persistent Asthma
116493 Completed Background incidence of cardiovascular ischaemic events in treated Parkinson's disease patients in the Impact database
116494 Withdrawn Case-control study to evaluate the vaccine effectiveness of Rotarix™ against rotavirus severe gastroenteritis among hospitalised children aged 12 weeks to less than 5 years, in Venezuela
116498 Completed An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fed conditions Study Listed on
116502 Completed An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart® 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart® 0.5mg and Omnic® 0.4mg Commercial Capsules in Healthy Male Subjects.
116505 Active, not recruiting A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
116509 Completed A serological study in adult subjects with Clostridium difficile infection
116511 Completed A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability,pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235 Study Listed on
116513 Relinquished A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
116516 Completed Community based patient questionnaire survey to assess asthma control in 4 Indian cities
116519 Completed The effect of food on the pharmacokinetics of metformin given either as metformin hydrochloride SR 1000mg tablet or as a fixed dose combination of metformin hydrochloride SR 1000mg/glimepiride 2mg tablet in healthy Indian volunteers.
116521 Completed An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy with Dabrafenib and the Combination of Dabrafenib with Trametinib in Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain
116524 Completed A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects Study Listed on
116526 Completed Bioequivalence of two levothyroxine tablet formulations in healthy Indian volunteers: A single-dose, randomized, open-label, crossover study
116529 Completed A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo over 7 Days in HIV-1-infected Subjects with RAL/ELV resistance, Followed by an Open-label Phase with an Optimized Background Regimen
116540 Relinquished An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 mutations
116543 Recruiting A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (belimumab)
116548 Completed Retrospective Study of the Prevalence, Predictors, and Consequences of Non-Adherence with Lapatinib in Women with Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab
116549 Completed Japanese smoker survey evaluating the prevalence of COPD in primary care patients.
116554 Completed Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.